Muhammad Inam

Dr. Muhammad Inam

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MIMuhammad Inam
Muhammad Inam
LLLu Liu
Lu Liu
JWJianwei Wang
Jianwei Wang
KYKa-Xi Yu
Ka-Xi Yu
CPChi Uyen Phan
Chi Uyen Phan
XHXiurong Hu
Xiurong Hu
Puerarin (PUE) is a Chinese traditional medicine known to enhance glucose uptake into the insulin cells to downregulate the blood glucose levels in the treatment of type II diabetes. Nevertheless, the bioavailability of pristine PUE is limited due to its poor solubility and low intestinal permeability. In this work, we demonstrate that the solubility of PUE can be significantly enhanced via its co-crystallization with L-Proline (PRO). Two crystalline phases, namely, the solvate-free form [PUE][PRO] (I) and the solvated form [PUE]2[PRO]∙EtOH∙(H2O)2 (II) are isolated. These two phases are characterized by single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), Fourier-transformed infrared (FT-IR) spectra, nuclear magnetic resonance (NMR), and thermogravimetric analysis in association with differential scanning calorimetry (TGA-DSC). The solubility and dissolution rate of both I and II in water, gastrointestinal tract at pH 1.2, and phosphate buffer at pH 6.8 indicates a nearly doubled increase as compared to the pristine PUE. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of pristine PUE, I and II against murine colon cancer cell lines CT-26 and human kidney cell lines HEK-293 indicated that neither compound exhibits obvious cytotoxicity after 24 h. This work showcases that the readily available and biocompatible PRO can be a promising adjuvant to enhance the physicochemical properties of PUE toward orally administered drug formulation with improved pharmacokinetics.

21 August 2018 in Crystals
Verified
Journal Article
Open access
PDF file
MIMuhammad Inam
Muhammad Inam
JWJiajia Wu
Jiajia Wu
JSJie Shen
Jie Shen
PUPhan Uyên
Phan Uyên
GTGuiliang Tang
Guiliang Tang
XHXiurong Hu
Xiurong Hu
Two new co-crystals, Ticagrelor with Nicotinamide, have been prepared with improved solubility. Because Ticalegor has a poor solubility and dissolution rate, a novel co-crystallization method with structurally homogenous crystalline material, an active pharmaceutical ingredient (API), and co-former indefinite stoichiometric amount has been made to improve Ticagrelor’s solubility. The co-crystal of Ticagrelor (TICA) with Nicotinamide (NCA) was prepared in ratio (1:1) and confirmed by FTIR, DSC, and XRD characterization. Furthermore, the single crystal structure of TICA-NCA hydrate was analyzed. The solubility of co-crystals was investigated in pH 2 acidic medium, which was a significant improvement as compared to the solubility of a free drug. The in vitro dissolution rate of co-crystal was larger than that of the commercial product.

14 October 2023 in Chemical Research in Chinese Universities
Verified
Journal Article
Closed access
PDF file
MIMuhammad Inam
Muhammad Inam
MSMoshirian-Farahi Sareh Sadat
Moshirian-Farahi Sareh Sadat
WCWENJIE CHEN
WENJIE CHEN
1

16 September 2024 in Journal of the Chinese Chemical Society
Verified
Journal Article
Closed access
MUMati Ullah
Mati Ullah
MSMuhammad Ijaz Shah
Muhammad Ijaz Shah
MHMuhammad Waqqas Hasan
Muhammad Waqqas Hasan
MJMuhammad Jamshed
Muhammad Jamshed
UMUswa Mustafa
Uswa Mustafa
MIMuhammad Inam
Muhammad Inam

21 March 2023 in Journal of the Chinese Chemical Society
Verified
Journal Article
Closed access
MIMuhammad Inam
Muhammad Inam
CPChi Uyen Phan
Chi Uyen Phan
JWJian‐Wei Wang
Jian‐Wei Wang
MJMuhammad Jamshed
Muhammad Jamshed
XHXiurong Hu
Xiurong Hu
GTGuping Tang
Guping Tang

2 December 2022 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
YYYi Yang
Yi Yang
DLDexu Luo
Dexu Luo
MIMuhammad Inam
Muhammad Inam
JHJialin Hu
Jialin Hu
YZYou Zhou
You Zhou
WCWenjie Chen
Wenjie Chen
Nanomedicine has been extensively studied for its versatility and broad-spectrum applications of theranostics in the research of respiratory disease. However, to the best of our knowledge, a scientometrics study based on the scientific knowledge assay of the overall situation on nanomedicine applied in the research of respiratory disease has not been reported so far, which would be of major importance to relevant researchers. To explore and exhibit the research status and developing trend of nanomedicines deployed in basic or clinical research in respiratory disease, the research ecosystem and exciting subareas were profiled based on the massive data mining and visualization from the relevant works reported from 2006 to 2021. Data were collected from the Web of Science database. Data statistics software and bibliometric analysis software were employed to visualize the research trend and the relationship between respiratory diseases and nanomedicines in each representative direction. The cluster analysis and burst detections indicated that the improvement of drug delivery and vaccine developments are the up-to-date key directions in nanomedicines for respiratory disease research and treatments. Furthermore, we emphatically studied four branch areas in this field including COVID-19, nanotube, respiratory syncytial virus, and mRNA vaccine those are selected for in-depth mining and bibliometric coupling analysis. Research trends signify the future focuses will center on preventing respiratory diseases with mRNA vaccines using nanoparticle-based approaches. We anticipate our study will enable researchers to have the panorama and deep insights in this area, thus inspiriting further exploitations especially the nanobiomaterial-based systems for theranostic applications in respiratory disease treatment.